single-center study that the short-term use of tolvaptan following LVAD implantation is a safe
and effective therapy to augment diuresis and improve hyponatremia. Their analysis …

Tolvaptan is an effective therapy for heart failure patients with symptomatic congestion and
hyponatremia. The efficacy of its use in patients with continuous-flow left ventricular assist …

Purpose Tolvaptan, a selective vasopressin type‐2 antagonist, has been shown to increase
serum sodium (Na) and urine output in hyponatremic left ventricular assist device (LVAD) …

Hypervolemic hyponatremia is often complicated with advanced heart failure together with
increased excretion of sodium by diuretics. Tolvaptan, an oral vasopressin-2-receptor …

Background: Loop diuretics are commonly used in heart failure (HF) patients, but they are
sometimes associated with insufficient response as well as adverse events. In such diuretics …

Aims Hyponatraemia is an electrolyte disorder that occurs in advanced congestive heart
failure (HF) and worsens prognosis. We explored the usefulness of tolvaptan, which has …

Several studies have demonstrated that tolvaptan (TLV) can improve hyponatremia in
advanced heart failure (HF) patients with rare chance of hypernatremia. However, changes …

Hyponatremia–usually defined by serum sodium< 135 mEq/L–is common in heart failure
(HF); it remains unclear whether it worsens HF or is merely a marker of more severe …

The survival rate in patients with advanced heart failure has improved owing to the
development of left ventricular assist devices (LVADs), which improves patients' …

Although the authors emphasize that the non-invasively estimated cardiac index, right
ventricular systolic pressure, and pulmonary wedge pressure values obtained from …